Bone and Cancer
Bone and Cancer
Bone and CancerBone and Cancer Foundation, PO Box 287452 Bone and Cancer New York, NY 10128-0025  
Toll Free: 888 862-0999 Bone and Cancer Email:  
Bone and Cancer

Clinical Trials


The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved April 2001

Specific Treatments:


Therapeutic Areas

General Information

PhosLo, in both capsule and gelcap formulations, has been approved for the control of hyperphosphatemia in end stage renal failure in adult patients. Patients suffering from kidney disease may experience increased blood levels of phosphate, which plays a pivotal role in causing secondary hyperpara-thyroidism associated with osteodystrophy and soft-tissue calcification. The rate of removal of phosphate by dialysis or by dietary manipulation is insufficient.

Clinical Results

Studies have confirmed that using calcium acetate as a phosphorus binder will control serum phosphorus levels in most dialysis outpatients.

Side Effects

Adverse events associated with the use of PhosLo capsules or gelcaps may include (but are not limited to) the following:

  • Nausea
  • Constipation
  • Vomiting
  • Stomach pains
  • Anorexia

Mechanism of Action

PhosLo (calcium acetate) binds to the phosphate taken in through one's diet to form insoluble calcium phosphate. This is then excreted from the body without being absorbed.

Additional Information

For additional information on PhosLo, please visit Braintree Laboratories.

 How To Order Publications:

Information About

Clinical Trials



















  Copyright 2011 - The Bone and Cancer Foundation